AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development
08/07/2026 – Appointment of Stéphane LEDERMANN as Chairman and Chief Executive Officer
Read more
therapies in diseases
with high medical need
Latest news
AB Science announces the successful completion of a EUR 2.3 million private placement
01/07/2026 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.3 million subscribed by a limited number of investors
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
29/06/2026 – AB Science today provides an update on the Phase 1 study of the molecule AB8939 and the completion of Step 3, evaluating the combination of AB8939 + venetoclax in patients with acute myeloid leukemia
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
17/06/2026 – AB Science today announced that the United States Patent Office has formally granted a patent for methods of treating metastatic castrate resistant prostate cancer (mCRPC) with its lead compound masitinib
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
09/06/2026 – AB Science today announced that new analyses from its phase 3 trial in amyotrophic lateral sclerosis (AB10015) have been accepted for poster presentation at the ENCALS annual meeting (June 24-26, 2026, Madrid, Spain)
Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share
02/06/2026 – Stonegate Capital Partners updates its coverage of AB Science’s stock with a discounted cash flow valuation mid-point of EUR 4.25 per share